肝爽颗粒联合熊去氧胆酸治疗原发性胆汁性胆管炎疗效观察  

Curative Effect of Ganshuang Granules(肝爽颗粒)Combined with Ursodeoxycholic Acid on PBC

作　　者：周保仓 曹亚伟 刘泉 赵晓婷 ZHOU Baocang;CAO Yawei;LIU Quan;ZHAO Xiaoting(The Third People's Hospital of Hengshui,Hengshui 053000,Hebei,China)

机构地区：[1]衡水市第三人民医院,河北衡水053000

出　　处：《辽宁中医杂志》2024年第5期135-138,共4页Liaoning Journal of Traditional Chinese Medicine

摘　　要：目的 探讨肝爽颗粒治疗原发性胆汁性胆管炎(primary biliary cholangitis, PBC)的疗效及对患者肝功能及肝纤维化的影响。方法 采用随机数字表法将于2019年12月—2022年3月在衡水市第三人民医院接受治疗的68例PBC患者分为A组和B组,各34例。A组给予熊去氧胆酸片,B组在A组基础上给予肝爽颗粒。两组均持续治疗3个月。比较两组治疗3个月后的疗效,治疗前、治疗3个月后的肝功能、肝纤维化指标、血清白细胞介素-6(interleukin-6,IL-6)、核因子相关因子2(Nrf2)、血红素加氧酶-1(hemoglobin oxygenase-1,HO-1),治疗期间的安全性。结果 B组治疗3个月后的总有效率为97.06%(33/34),高于A组的76.47%(26/34)(P<0.05)。两组治疗3个月后的血清天冬氨酸转氨酶(aspartate aminotransferase, AST)、丙氨酸转氨酶(alanine aminotransferase, ALT)、γ-谷氨酰转肽酶(γ-glutamyl transpeptidase, GGT)、透明质酸(hyaluronic acid, HA)、层黏连蛋白(laminin, LN)、Ⅲ型前胶原肽(typeⅢprocollagen peptide, PCⅢ)及IL-6水平均比治疗前低,且与A组进行比较,B组较低;两组治疗3个月后的血清Nrf2、HO-1水平均比治疗前高,且与A组进行比较,B组高于A组(P<0.05)。B组及A组治疗期间的不良反应发生率比较,差异无统计学意义[17.65%(6/34) vs 11.76%(4/34),P>0.05]。结论 肝爽颗粒可有效减轻PBC患者炎症反应及氧化应激反应,并抑制患者肝纤维化,进一步提高患者肝功能,具有较高临床疗效,且其安全性良好。Objective To investigate the therapeutic effect of Ganshuang Granule(肝爽颗粒)on primary biliary cholangitis(PBC)and its influence on liver function and liver fibrosis.Methods A total of 68 patients with PBC who were treated in the hospital from December 2019 to March 2022 were divided into the group A and the group B by random number table method,34 cases in each group.The group A was given ursodeoxycholic acid tablets,and the group B was given Ganshuang Granule on the basis of the group A.Both groups were treated continuously for 3 months.The curative effect of the two groups after 3 months of treatment,liver function,liver fibrosis indexes,serum nuclear factor-related factor 2(Nrf2),interleukin(IL-6)and hemoglobin oxy-genase-1(HO-1)before treatment and after 3 months of treatment and the safety during treatment between two groups were compared.Results The total effective rate in the group B after 3 months of treatment was 97.06%(33/34),which was higher than 76.47%(26/34)in the group A(P<0.05).After 3 months of treatment,the levels of serum aspartate aminotransferase(AST),alanine aminotransferase(ALT),γ-glutamyl transpeptidase(GGT),hyaluronic acid(HA),laminin(LN),type III procollagen peptide(PCⅢ)and IL-6 in the two groups were lower than those before treatment,and compared with those of the group A,those of the group B were lower.After 3 months of treatment,the levels of serum Nrf2 and HO-1 in the two groups were higher than those before treatment,and compared with those of the group A,the levels in the group B were higher(P<0.05).There was no significant difference in the incidence of adverse reactions between the group B and the group A during the treatment period[17.65%(6/34)vs 11.76%(4/34),P>0.05].Conclusion Ganshuang Granule could effectively reduce the inflammatory response and oxidative stress in patients with PBC,inhibit liver fibrosis and further improve the liver function of patients.It had high clinical efficacy and good safety.

关 键 词：原发性胆汁性胆管炎 熊去氧胆酸 肝爽颗粒 肝功能 

分 类 号：R256.4[医药卫生—中医内科学]